Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
Authors
Keywords
-
Journal
DRUGS
Volume 79, Issue 3, Pages 271-289
Publisher
Springer Nature
Online
2019-02-02
DOI
10.1007/s40265-019-1055-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
- (2018) Nao Kawaguchi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
- (2018) Yutaka Saisho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
- (2018) Ronald Domalaon et al. CLINICAL MICROBIOLOGY REVIEWS
- Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model
- (2018) Islam M. Ghazi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa
- (2018) Islam M. Ghazi et al. PHARMACOLOGY
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
- (2017) J. Dobias et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
- (2017) Matthew E. Falagas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
- (2016) Tsukasa Ito-Horiyama et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Global Dissemination ofblaKPCinto Bacterial Species beyond Klebsiella pneumoniae andIn VitroSusceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam
- (2016) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function
- (2016) Takayuki Katsube et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
- (2016) Takayuki Katsube et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The global epidemiology of carbapenemase-producing Enterobacteriaceae
- (2016) David van Duin et al. Virulence
- In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
- (2015) Naoki Kohira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Improving predictions of the risk of resistance development against new and old antibiotics
- (2015) D.I. Andersson CLINICAL MICROBIOLOGY AND INFECTION
- In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
- (2015) Akinobu Ito et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action
- (2012) Jean Carlet et al. Antimicrobial Resistance and Infection Control
- Carbapenems: Past, Present, and Future
- (2011) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
- (2011) N. Gupta et al. CLINICAL INFECTIOUS DISEASES
- Updated Functional Classification of -Lactamases
- (2009) K. Bush et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AmpC -Lactamases
- (2009) G. A. Jacoby CLINICAL MICROBIOLOGY REVIEWS
- Global spread of carbapenem-resistant Acinetobacter baumannii
- (2009) P. G. Higgins et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started